乌司他丁对糖尿病酮症酸中毒合并胰腺炎患者体内CX3CL1、HMGB1含量的影响

Effect of Ulinastatin on the Content of CX3CL1 and HMGB1 in Patients with Diabetic Ketoacidosis complicated with Pancreatitis

目的探讨乌司他丁对糖尿病酮症酸中毒合并胰腺炎患者胰腺组织内趋化因子CX3CL1、高迁移率族蛋白B1(HMGB1)含量的影响。方法选取我院2013年1月至2017年12月收治的糖尿病酮症酸中毒合并胰腺炎患者40例,按照随机数字表法均分为观察组和对照组,每组20例。对照组患者给予常规西药治疗,观察组患者在此基础上加用乌司他丁治疗。观察两组患者测胰腺组织CX3CL1、HMGB1水平变化并进行比较分析。结果治疗前两组患者HMGB1、TNF-α、CX3CL1、血液淀粉酶、血糖、血酮体表达水平比较,差异无统计学意义(P> 0. 05);同组治疗前后相比,两组患者HMGB1、TNF-α、CX3CL1、血液淀粉酶、血糖、血酮体水平均显著降低,观察组明显低于对照组,两组之间差异有统计学意义(P<0. 05)。观察组的血淀粉酶恢复正常时间,腹痛腹胀缓解时间均明显短于对照组,差异有统计学意义(P<0. 05)。结论乌司他丁可降低糖尿病酮症酸中毒合并胰腺炎患者体内CX3CL1、HMGB1含量,并有效改善临床症状,提高疗效。

Objective To investigate the effect of ulinastatin on the content of CX3CL1 and high mobility group protein B1(HMGB1)in pancreatic tissue of patients with diabetic ketoacidosis complicated with pancreatitis.Methods 40 patients with diabetic ketoacidosis complicated with pancreatitis admitted and treated in our hospital from January 2013 to December 2017 were selected and divided into observation group and control group according to the random number table method,with 20 cases in each group.Patients in the control group were treated with conventional western medicine,and patients in the observation group were treated with ulinastatin on this basis.The changes of CX3CL1 and HMGB1 levels in pancreatic tissues of the two groups were observed and compared.Results There was no statistically significant difference in HMGB1,tnf-alpha,CX3CL1,blood amylase,blood glucose,and ketosome expression levels between the two groups before treatment(P﹥0.05).Compared with the control group before and after treatment,HMGB1,tnf-alpha,CX3CL1,blood amylase,blood glucose and ketosome levels in the two groups were significantly lower than those in the observation group,and the differences between the two groups were statistically significant(P﹤0.05).The normal time of blood amylase recovery and the relief time of abdominal pain and distension in the observation group were significantly shorter than those in the control group,with statistically significant differences(P﹤0.05).Conclusion Ulinastatin can reduce the content of CX3CL1 and HMGB1 in patients with diabetic ketoacidosis complicated with pancreatitis,and effectively improve clinical symptoms and efficacy.